tirzepatide dual agonist Tirzepatide, a GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction | Cardiovascular Diabetology Compounded tirzepatide telehealth from Fitish RX The Tirzepatide Revolution: Is Dual

MariTide Name: Maridebart cafraglutide (MariTide, formerly AMG 133) Manufacturer: Amgen Current stage: US phase III trial currently underway (MARITIME, NCT06858839) Takeaway: The dual agonist/antagonist action of MariTide could promise higher weight loss with fewer side effects, with dosing at less frequent intervals but more studies are needed

A meta-analysis of 82 studies involving over 213,000 survivors found that women with obesity had a 41% higher risk of dying from any cause compared with women at a healthy weight

Conclusions We have shown a simple and effective method for conjugating glutathione to PEGDA

Weight loss medications In addition to dietary and lifestyle modification, the use of weight loss medications should be considered for patients with weight regain after sleeve gastrectomy